Take the Diabetes Health Pump Survey
Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Diabetes Health Mobile App
Latest
Popular
Top Rated

Latest Type 1 Issues Articles

Finding the Right Diabetes Doctor
Around the Table: A Dinner Host's Responsibility With Paula Deen
“Reprogrammed” Cells in Mice Reverse Late-stage Type 1 Diabetes
Insulin degludec
All in the Family
Neuropathy Device Maker Files
Driving Safely With Type 1 Diabetes
Pregnancy, Parenting, Writing, and Diabetes: An Interview With Cheryl Alkon
Sam Talbot, Top Chef
Type 1 Diabetes Researchers Reach Important Milestone
Diabetes Health Reference Charts
Insulin Reference Guide (PDF)
Syringes Reference Guide (PDF)
Insulin Pen Needles Reference Guide (PDF)
Insulin Pumps Reference Guide (PDF)
Blood Glucose Meters Reference Guide (PDF)
Mail Order Reference Guide (PDF)
Lancing Devices Reference Guide (PDF)
Continuous Glucose Monitors Reference Guide (PDF)
Infusion Sets Reference Guide (PDF)
Fast Acting Glucose Reference Guide (PDF)
See All Charts…
Type 1 Issues Archives
Browse the Type 1 Issues Archives
Subscribe to the Community RSS Feed
Print | Email | Share | Comments (0)

Amylin, JDRF Team to Test Symlin/Insulin Combo for Type 1


Jun 3, 2011

Symlin and Insulin for Type 1's

Amylin Pharmaceuticals has announced that it will collaborate with the Juvenile Diabetes Research Foundation to test a combination of Symlin and insulin in injectible form as a type 1 therapy.

Currently, people with type 1 diabetes who take Symlin and insulin inject them separately. The test will determine if taking the two together increases blood sugar control by reducing the number of separate daily injections, making it easier for type 1s to manage the disease.

Symlin (pramlintide acetate) is an artificial analog of amylin, which is a hormone the pancreas secretes into the bloodstream along with insulin after a meal. In people with diabetes, amylin may be deficient or non-existent.

Symlin works by promoting a sense of satiety, slowing gastric emptying-which helps with the absorption of glucose-and inhibiting glucagon secretion.  

The Amylin Pharmaceuticals-JDRF collaboration is the second one that the two partners have entered over the past year. In November, they announced that they would test whether metreleptin, a leptin mimic, can improve blood sugar control to the point of lowering the daily insulin dose required by patients with diabetes.

Categories: , Amylin Pharmaceuticals, Blood Glucose, Blood Sugar, Diabetes, Diabetes, Glucagon, Injection, JDRF, Symlin, Type 1 Issues

Donate to Diabetes Health

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - Jun 3, 2011

©1991-2012 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.